Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
How a nephrology unit cut C. diff infections by 90%
3+ hour, 50+ min ago (948+ words) A US inpatient nephrology unit was able to reduce hospital-acquired Clostridioides difficile (C. diff) infections by 90% after implementing nurse-driven protocols, reports MedPage Today. Between January and April 2023, Detroit’s Henry Ford Hospital nephrology unit recorded a hospital-onset C. diff infection (HO-CDI) rate…...
Revolution Medicines nabs approval of pancreatic cancer therapy daraxonrasib
6+ hour, 36+ min ago (15+ words) FDA approves Revolution Medicines’ Rasonque (daraxonrasib), a first-in-class RAS inhibitor for pancreatic cancer, boosting survival....
FDA Approves First-Of-Its-Kind Pancreatic Cancer Drug
5+ hour, 15+ min ago (147+ words) Revolution Medicines won FDA approval Wednesday for the pancreatic cancer treatment that once caused its stock to skyrocket. The post FDA Approves 'Unprecedented' Pancreatic Cancer Drug appeared first on Investor's Business Daily. BREAKING: Fed Inflation Data Puts Pressure On Warsh…...
FDA approves ‘landmark’ pancreatic cancer drug that extends patients’ lives
1+ hour ago (126+ words) Breaking news and analysis on politics, business, world, national news, entertainment and more. In-depth DC, Virginia, Maryland news coverage including traffic, weather, crime, education, restaurant reviews and more. In trials, Revolution Medicines’ daraxonrasib nearly doubled average survival times for one…...
Revolution Medicines gets FDA nod for targeted pancreatic cancer drug - CNN
1+ hour, 3+ min ago (253+ words) The U.S. Food and Drug Administration on Wednesday approved Revolution Medicines’ targeted drug for adults with metastatic pancreatic cancer who have received prior treatment or cannot receive combination chemotherapy. The drug, branded as Rasonque and also known as daraxonrasib, is a…...
'Grand Slam' Pancreatic Cancer Drug Wins FDA Approval
5+ hour, 22+ min ago (418+ words) — RAS inhibitor daraxonrasib doubled survival outcomes in second-line trial The FDA approved the first-in-class RAS inhibitor daraxonrasib (Rasonque) for metastatic pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer. The approval stipulates use in adults with PDAC previously…...
FDA approves landmark pancreatic cancer drug that's shown to improve survival
1+ hour, 21+ min ago (38+ words) U.S. health officials have approved a groundbreaking pancreatic cancer drug that offers a new approach to treating the deadly form of cancer....
FDA Approves Rasonque (Daraxonrasib), First-in-Class Targeted Therapy for Metastatic Pancreatic Cancer
6+ hour, 16+ min ago (292+ words) The U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer, delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule. This action demonstrates the agency’s…...
Revolution Medicines gets FDA nod for targeted pancreatic cancer drug
6+ hour, 8+ min ago (131+ words) Aug 26 (Reuters) – The U.S. Food and Drug Administration on Wednesday approved Revolution Medicines’ targeted drug for adults with metastatic pancreatic cancer who have received prior treatment or cannot receive combination chemotherapy. The drug, branded as Rasonque and also known as…...
Unlocking secrets to better outcomes
1+ day, 6+ hour ago (349+ words) Olúwatóyìn Ajíbọ́lá Aṣojò, PHD The American Cancer Society (ACS) wants to hear Black women’s voices. ACS launched a groundbreaking population cohort study — VOICES of Black Women — underscoring ACS’s commitment to better understand why Black women are impacted by cancer…...